FindTrial
Sign In

CEA als biomarker bij longcarcinoom

Prognostic value of serum carcinoembryonic antigen in advanced (non-)small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON25617
Enrollment
500
Registered
2016-06-28
Start date
2016-07-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(N)SCLC Biomarker CEA

Interventions

Retrospective observational study

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I. Advanced (N)SCLC patients who received conventional chemotherapy, targeted therapy or immunotherapy between 2009-2016. II. CEA levels available prior to treatment (baseline), on week 3, 6 and 12.

Exclusion criteria

Exclusion criteria: Subjects who do not meet inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Correlation of CEA decline (when CEA initially is increased (>5.0 ng/mL)) and OR (conform RECIST 1.1 criteria).—

Secondary

MeasureTime frame
I. The correlation of decline of CEA levels and overall survival (OS). II. The correlation of decline of CEA levels and the occurrence of brain metastases. III. The correlation of decline of CEA levels and OR on different treatment strategies (conventional chemotherapy, targeted therapy and immunotherapy).—

Contacts

Public ContactD. C. de Jong

St. Antoniusziekenhuis

dc.de.jong@antoniusziekenhuis.nl088-3207278

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)